Nesvacumab, a fully human immunoglobulin G1 (IgG1) monoclonal antibody, selectively binds to and inactivates Angiopoietin-2 (Ang2), the ligand for the Tie2 receptor, with high affinity, while exhibiting no affinity for Angiopoietin-1 (Ang1) [1].